Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

CONCLUSIONS: The benefit of N+F+T for HR+ HER2-mutant MBC after progression on CDK4/6 inhibitors is clinically meaningful and, based on this study, N+F+T has been included in National Comprehensive Cancer Network treatment guidelines. SUMMIT has improved our understanding of the translational implications of targeting HER2 mutations with neratinib-based therapy.PMID:37597578 | DOI:10.1016/j.annonc.2023.08.003

Source: Ann Oncol - August 19, 2023 Category: Cancer & Oncology Authors: K Jhaveri L D Eli H Wildiers S A Hurvitz A Guerrero-Zotano N Unni A Brufsky H Park J Waisman E S Yang I Spanggaard S Reid M E Burkard S Vinayak A Prat M Arnedos F-C Bidard S Loi J Crown M Bhave S A Piha-Paul J M Suga S Chia C Saura J Á Garcia-Saenz V Gam Source Type: research